Roswell Park Presents Highly Encouraging Phase 2A Results on SurVaxM Immunotherapy for Glioblastoma
Results of phase 2A single-arm trial assessing SurVaxM plus standard therapy highlighted in poster at ASCO 2022.
Source: pressreleasepoint.com
Stay updated with breaking news from Robert Fenstermaker. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results of phase 2A single-arm trial assessing SurVaxM plus standard therapy highlighted in poster at ASCO 2022.